Diurnal seeks marketing authorisation for Chronocort in the UK
MHRA submission is based on same application filed with the EMA
Read More
Tag: congenital adrenal hyperplasia
Diurnal files Chronocort in the EU
If approved, the firm will be able to offer lifelong treatment for the rare condition congenital adrenal hyperplasia
Read More
Diurnal shares plummet on trial failure
Shares in UK speciality pharma Diurnal plummeted more than 50 percent on news that a late-stage study of an experimental treatment for congenital adrenal hyperplasia (CAH) failed to meet its primary objective.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
